SCHEMBL2653975

SCHEMBL2653975

CS(=O)(=O)c1ccc(/C(=C\C2CCCCC2)CO)cc1OC(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 3/20 0.36
DDR1 Q08345 6/20 0.34
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
PAX8 Q06710 1/20 0.33
THRB P10828 4/20 0.33
KCNH2 Q12809 2/20 0.33
TMEM97 Q5BJF2 2/20 0.33
SIGMAR1 Q99720 2/20 0.33
PPARG P37231 2/20 0.33
VDR P11473 1/20 0.33
PTPN1 P18031 1/20 0.33
OPRM1 P35372 1/20 0.32
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4484364 1.00 GCK (0.36) GCKDDR1CNR1CNR2PAX8
SCHEMBL1581776 0.82 GCK (0.40) GCKTHRBKCNH2PPARGVDR
SCHEMBL1581778 0.82 GCK (0.40) GCKTHRBKCNH2PPARGVDR
SCHEMBL4483872 0.74 KMT2A (0.49) GCKMEN1KMT2A
SCHEMBL1581754 0.74 KMT2A (0.49) GCKMEN1KMT2A
SCHEMBL1581752 0.74 KMT2A (0.49) GCKMEN1KMT2A
SCHEMBL1582009 0.72 KMT2A (0.47) GCKKMT2A
SCHEMBL1582005 0.72 KMT2A (0.47) GCKKMT2A
SCHEMBL4486333 0.72 KMT2A (0.47) GCKKMT2A
SCHEMBL4472935 0.72 ALDH1A1 (0.42) CNR2LMNAHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY 2006-05-25 US disclosed
EP-1585739-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2005-10-19 EP disclosed
WO-2004063179-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators GCK, GCKR, GALK1 GCK 1/4885DDR1 4629/4885CNR1 2265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.